Who this is for
Men who have been newly diagnosed with metastatic prostate cancer, particularly those found to carry a BRCA2 mutation, and their families who want to understand whether adding a PARP inhibitor earlier may improve outcomes.
This article may also be helpful for patients seeking a prostate cancer second opinion in Melbourne, Australia, or from Sri Lanka, the Maldives, Indonesia, or the Philippines.
Clinical observation
A 59-year-old man is diagnosed with prostate cancer that has spread to the bones. Genetic testing identifies a BRCA2 mutation. Traditionally, treatment would involve hormone-lowering injections together with a hormone-blocking tablet such as abiraterone. The question is whether adding a PARP inhibitor from the very beginning can keep the cancer under control for longer.
Why this matters
Most prostate cancers are initially driven by male hormones such as testosterone. Treatments that lower or block these hormones often work very well at the beginning.
However, men with BRCA2-mutated prostate cancer can have a higher-risk form of the disease.
Because of this, researchers wanted to know whether introducing a PARP inhibitor earlier could delay cancer progression and improve outcomes.
What did the AMPLITUDE trial test?
The AMPLITUDE trial studied men with newly diagnosed metastatic castration-sensitive prostate cancer.
All patients had an alteration in a DNA repair gene, also called an HRR gene.
This included men with BRCA1, BRCA2 and other DNA repair gene alterations.
The study included 696 men from international centres.
Patients received one of two treatment approaches:
- Hormone-lowering treatment plus abiraterone and prednisone
- Hormone-lowering treatment plus abiraterone, prednisone and niraparib
Niraparib is a PARP inhibitor.
In simple terms, the study asked:
Could adding a PARP inhibitor from the beginning keep the cancer controlled for longer?
Key results
- The cancer stayed controlled for longer on scans.
Overall, adding niraparib reduced the risk of the cancer growing on scans or the patient dying by approximately 37%. - The benefit was stronger in men with BRCA1 or BRCA2 mutations.
In this group, adding niraparib reduced the risk of the cancer worsening on scans or the patient dying by approximately 48%. - The strongest signal appeared to be in men with BRCA2 mutations.
Further analysis suggested that much of the benefit in the study came from the BRCA2-positive group. - Overall survival results are still early.
Early results favoured the niraparib group, but follow-up is not yet long enough to confirm a clear survival benefit. - Side effects were more common with the added treatment.
The main additional side effect was anaemia, meaning a low red blood cell count. Some patients needed dose changes, treatment breaks or blood transfusions.
Safety
The combination was generally manageable but did cause more side effects than standard treatment alone.
The most common additional side effect was anaemia (low red blood cell count).
Some patients required dose reductions, treatment interruptions, or blood transfusions. Despite this, most patients were able to continue treatment.
What this means for you
If you have metastatic prostate cancer and carry a BRCA2 mutation, AMPLITUDE suggests that treatment may be more effective when intensified from the beginning.
This does not mean every patient should receive this combination.
The decision depends on the type of mutation, overall health, blood counts, other medical conditions, treatment access and personal preferences.
The study also reinforces the importance of genetic and genomic testing when metastatic prostate cancer is diagnosed.
For many patients with BRCA2-positive metastatic prostate cancer, the conversation is increasingly moving from:
“What should we do when the cancer grows?”
to
“What should we do now to delay that happening for as long as possible?”
Overall, BRCA2-positive metastatic prostate cancer is an area where early genetic testing may change the treatment discussion from the beginning.
Key takeaways
- BRCA2-positive metastatic prostate cancer can behave differently
Genetic testing can help identify men whose cancer may need a more personalised treatment approach from the beginning. - Earlier treatment intensification may help selected patients
The AMPLITUDE trial suggests that adding a PARP inhibitor early may keep the cancer controlled for longer in selected men with DNA repair gene alterations. - The BRCA2 group appears especially important
The strongest treatment signal appeared to come from men with BRCA2-mutated prostate cancer. - Genetic testing should be discussed early
For men diagnosed with metastatic prostate cancer, early genetic testing may help guide treatment choices and family risk discussions if the mutation is inherited.
Key evidence
- Attard G, Agarwal N, Graff JN, et al. Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial. Nat Med. 2025;31(12):4109-4118. doi:10.1038/s41591-025-03961-8
- ClinicalTrials.gov. AMPLITUDE: a study of niraparib in combination with abiraterone acetate and prednisone versus abiraterone acetate and prednisone for metastatic prostate cancer. ClinicalTrials.gov identifier: NCT04497844. Accessed June 6, 2026. https://clinicaltrials.gov/study/NCT04497844
- European Society for Medical Oncology. Combining niraparib with abiraterone acetate and prednisone significantly improves rPFS in patients with mCSPC harbouring BRCA1/2 or other HRR gene alterations. ESMO Oncology News. Published October 22, 2025. Accessed June 8, 2026. https://www.esmo.org/oncology-news/combining-niraparib-with-abiraterone-acetate-and-prednisone-significantly-improves-rpfs-in-patients-with-mcspc-harbouring-brca1-2-or-other-hrr-gene-alterations
Dr Dilanka De Silva
MBBS, MRCP(UK), MRCP(UK SCE Oncology), FRACP, PhD
Medical Oncologist & Cancer Genetics Physician
Memorial Sloan Kettering Cancer Center Fellow (New York, USA)